539 related articles for article (PubMed ID: 24434846)
21. Human adipose tissue possesses a unique population of pluripotent stem cells with nontumorigenic and low telomerase activities: potential implications in regenerative medicine.
Ogura F; Wakao S; Kuroda Y; Tsuchiyama K; Bagheri M; Heneidi S; Chazenbalk G; Aiba S; Dezawa M
Stem Cells Dev; 2014 Apr; 23(7):717-28. PubMed ID: 24256547
[TBL] [Abstract][Full Text] [Related]
22. Gene expression signatures defining fundamental biological processes in pluripotent, early, and late differentiated embryonic stem cells.
Gaspar JA; Doss MX; Winkler J; Wagh V; Hescheler J; Kolde R; Vilo J; Schulz H; Sachinidis A
Stem Cells Dev; 2012 Sep; 21(13):2471-84. PubMed ID: 22420508
[TBL] [Abstract][Full Text] [Related]
23. VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion.
Lahlil R; Scrofani M; Barbet R; Tancredi C; Aries A; Hénon P
Stem Cell Rev Rep; 2018 Aug; 14(4):510-524. PubMed ID: 29736843
[TBL] [Abstract][Full Text] [Related]
24. Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask.
Want AJ; Nienow AW; Hewitt CJ; Coopman K
Regen Med; 2012 Jan; 7(1):71-84. PubMed ID: 22168499
[TBL] [Abstract][Full Text] [Related]
25. Isolation and culture of pig epiblast stem cells.
Rodriguez A; Contreras DA; Alberio R
Methods Mol Biol; 2013; 1074():97-110. PubMed ID: 23975808
[TBL] [Abstract][Full Text] [Related]
26. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids.
Freedman BS; Brooks CR; Lam AQ; Fu H; Morizane R; Agrawal V; Saad AF; Li MK; Hughes MR; Werff RV; Peters DT; Lu J; Baccei A; Siedlecki AM; Valerius MT; Musunuru K; McNagny KM; Steinman TI; Zhou J; Lerou PH; Bonventre JV
Nat Commun; 2015 Oct; 6():8715. PubMed ID: 26493500
[TBL] [Abstract][Full Text] [Related]
27. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
28. Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise.
Duelen R; Sampaolesi M
EBioMedicine; 2017 Feb; 16():30-40. PubMed ID: 28169191
[TBL] [Abstract][Full Text] [Related]
29. Defining the nature of human pluripotent stem cell progeny.
Patterson M; Chan DN; Ha I; Case D; Cui Y; Van Handel B; Mikkola HK; Lowry WE
Cell Res; 2012 Jan; 22(1):178-93. PubMed ID: 21844894
[TBL] [Abstract][Full Text] [Related]
30. Induced pluripotent stem cells: reprogrammed without a trace.
Nelson TJ; Terzic A
Regen Med; 2009 May; 4(3):333-5. PubMed ID: 19438303
[No Abstract] [Full Text] [Related]
31. The advancement of human pluripotent stem cell-derived therapies into the clinic.
Thies RS; Murry CE
Development; 2015 Sep; 142(18):3077-84. PubMed ID: 26395136
[TBL] [Abstract][Full Text] [Related]
32. Production of human pluripotent stem cell therapeutics under defined xeno-free conditions: progress and challenges.
Fan Y; Wu J; Ashok P; Hsiung M; Tzanakakis ES
Stem Cell Rev Rep; 2015 Feb; 11(1):96-109. PubMed ID: 25077810
[TBL] [Abstract][Full Text] [Related]
33. The Progression of Regenerative Medicine and its Impact on Therapy Translation.
Jacques E; Suuronen EJ
Clin Transl Sci; 2020 May; 13(3):440-450. PubMed ID: 31981408
[TBL] [Abstract][Full Text] [Related]
34. DNA and chromatin modification networks distinguish stem cell pluripotent ground states.
Song J; Saha S; Gokulrangan G; Tesar PJ; Ewing RM
Mol Cell Proteomics; 2012 Oct; 11(10):1036-47. PubMed ID: 22822199
[TBL] [Abstract][Full Text] [Related]
35. The 'sweet' spot of cellular pluripotency: protein glycosylation in human pluripotent stem cells and its applications in regenerative medicine.
Wang YC; Lin V; Loring JF; Peterson SE
Expert Opin Biol Ther; 2015 May; 15(5):679-87. PubMed ID: 25736263
[TBL] [Abstract][Full Text] [Related]
36. CSCs and pluripotent/multipotent stem cells.
Lab Invest; 2017 Oct; 97(10):1124-1125. PubMed ID: 28961234
[No Abstract] [Full Text] [Related]
37. Characterization of companion animal pluripotent stem cells.
Paterson YZ; Kafarnik C; Guest DJ
Cytometry A; 2018 Jan; 93(1):137-148. PubMed ID: 28678404
[TBL] [Abstract][Full Text] [Related]
38. Human pituitary development and application of iPSCs for pituitary disease.
Matsumoto R; Takahashi Y
Cell Mol Life Sci; 2021 Mar; 78(5):2069-2079. PubMed ID: 33206204
[TBL] [Abstract][Full Text] [Related]
39. Unique properties of a subset of human pluripotent stem cells with high capacity for self-renewal.
Lau KX; Mason EA; Kie J; De Souza DP; Kloehn J; Tull D; McConville MJ; Keniry A; Beck T; Blewitt ME; Ritchie ME; Naik SH; Zalcenstein D; Korn O; Su S; Romero IG; Spruce C; Baker CL; McGarr TC; Wells CA; Pera MF
Nat Commun; 2020 May; 11(1):2420. PubMed ID: 32415101
[TBL] [Abstract][Full Text] [Related]
40. An alternative pluripotent state confers interspecies chimaeric competency.
Wu J; Okamura D; Li M; Suzuki K; Luo C; Ma L; He Y; Li Z; Benner C; Tamura I; Krause MN; Nery JR; Du T; Zhang Z; Hishida T; Takahashi Y; Aizawa E; Kim NY; Lajara J; Guillen P; Campistol JM; Esteban CR; Ross PJ; Saghatelian A; Ren B; Ecker JR; Izpisua Belmonte JC
Nature; 2015 May; 521(7552):316-21. PubMed ID: 25945737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
